NO994506D0 - Methods and compositions for modulating susceptibility to corticosteroids - Google Patents
Methods and compositions for modulating susceptibility to corticosteroidsInfo
- Publication number
- NO994506D0 NO994506D0 NO994506A NO994506A NO994506D0 NO 994506 D0 NO994506 D0 NO 994506D0 NO 994506 A NO994506 A NO 994506A NO 994506 A NO994506 A NO 994506A NO 994506 D0 NO994506 D0 NO 994506D0
- Authority
- NO
- Norway
- Prior art keywords
- corticosteroids
- compositions
- methods
- modulating susceptibility
- susceptibility
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title 1
- 229960001334 corticosteroids Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/820,692 US6054487A (en) | 1997-03-18 | 1997-03-18 | Methods and compositions for modulating responsiveness to corticosteroids |
| US1634698A | 1998-01-30 | 1998-01-30 | |
| PCT/US1998/004916 WO1998041232A2 (en) | 1997-03-18 | 1998-03-12 | Compositions for modulating responsiveness to corticosteroids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO994506D0 true NO994506D0 (en) | 1999-09-17 |
| NO994506L NO994506L (en) | 1999-11-17 |
Family
ID=26688484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO994506A NO994506L (en) | 1997-03-18 | 1999-09-17 | Methods and compositions for modulating susceptibility to corticosteroids |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0998300A1 (en) |
| JP (1) | JP2002504091A (en) |
| KR (1) | KR20000076420A (en) |
| CN (1) | CN1269722A (en) |
| AU (1) | AU734756B2 (en) |
| BG (1) | BG103808A (en) |
| BR (1) | BR9810409A (en) |
| CA (1) | CA2282845A1 (en) |
| DE (1) | DE998300T1 (en) |
| ES (1) | ES2146192T1 (en) |
| HU (1) | HUP0104439A3 (en) |
| ID (1) | ID22975A (en) |
| IL (1) | IL131815A0 (en) |
| NO (1) | NO994506L (en) |
| NZ (1) | NZ337769A (en) |
| PL (1) | PL336464A1 (en) |
| SI (1) | SI20110A (en) |
| SK (1) | SK122199A3 (en) |
| TR (1) | TR199902615T2 (en) |
| WO (1) | WO1998041232A2 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6830751B1 (en) | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
| ZA95960B (en) * | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| AR015966A1 (en) * | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | USE OF A PDE4 INHIBITOR COMPOUND FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR PRURITE TREATMENT |
| EP1516630A3 (en) * | 1997-10-31 | 2006-05-03 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
| EP0969867B1 (en) * | 1997-10-31 | 2004-09-01 | Wyeth | Use of anti-il-12 antibodies in transplantation rejection |
| WO1999025737A1 (en) * | 1997-11-19 | 1999-05-27 | Tanox Pharma B.V. | Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain |
| JP2002506829A (en) * | 1998-03-16 | 2002-03-05 | サイトビア インコーポレイテッド | Apoptosis inhibitors of dipeptides and their uses |
| WO2001045747A1 (en) * | 1998-11-27 | 2001-06-28 | Technion Research & Development Foundation Ltd. | Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis |
| EP1137766B1 (en) * | 1998-12-09 | 2005-09-28 | Protein Design Labs, Inc. | Use of il-12 antibodies to treat psoriasis |
| ATE336480T1 (en) | 1999-03-16 | 2006-09-15 | Cytovia Inc | SUBSTITUTED 2-AMINOBENZAMIN CASPASE INHIBITORS AND THEIR USE |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| DE19915465A1 (en) * | 1999-04-06 | 2000-10-19 | Apotech Res & Dev Ltd | Use of a caspase inhibitor to inhibit cell proliferation and use of one or more caspase inhibitors to treat diseases based on lymphocyte hyperproliferation or to suppress an immune response by lymphocytes |
| JP2002541237A (en) | 1999-04-09 | 2002-12-03 | サイトビア インコーポレイテッド | Caspase inhibitors and uses thereof |
| IL131047A0 (en) * | 1999-07-22 | 2001-01-28 | Yeda Res & Dev | Use of il-18 inhibitors |
| DE60040397D1 (en) | 1999-08-27 | 2008-11-13 | Cytovia Inc | SUBSTITUTED ALPHA HYDROXY ACIDS AS CASPASE INHIBITORS AND THEIR USE |
| WO2001019373A2 (en) * | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6566338B1 (en) | 1999-10-12 | 2003-05-20 | Cytovia, Inc. | Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| CN102206277A (en) | 2000-02-10 | 2011-10-05 | 雅培制药有限公司 | Antibodies that bind human interleukin-18 and methods of making and using |
| EP1289557B1 (en) * | 2000-06-06 | 2006-07-12 | Glaxo Group Limited | Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor |
| AU7250301A (en) * | 2000-06-22 | 2002-01-02 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
| US20020025317A1 (en) * | 2000-07-20 | 2002-02-28 | Schering Ag | Bispecific monoclonal antibodies to IL-12 and IL-18 |
| WO2002022127A1 (en) * | 2000-09-13 | 2002-03-21 | Isis Innovation Limited | Use of phosphodiesterase inhibitors for the treatment of anorectal disorders |
| EP1188438A1 (en) * | 2000-09-15 | 2002-03-20 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| CZ305653B6 (en) * | 2001-01-29 | 2016-01-27 | Merck Serono Sa | Pharmaceutical composition |
| IL158866A0 (en) * | 2001-05-16 | 2004-05-12 | Yeda Res & Dev | Use of il-18 inhibitors for the treatment or prevention of sepsis |
| EP3492100B1 (en) | 2001-06-26 | 2021-12-08 | Amgen Inc. | Antibodies to opgl |
| HRP20040388A2 (en) * | 2001-10-05 | 2004-10-31 | Combinatorx | Combinations for the treatment of immunoinflammatory disorders |
| JP2003342196A (en) * | 2002-05-31 | 2003-12-03 | Mukku:Kk | Composition for intravenous injection, method of production for the same and its preparation |
| WO2004030618A2 (en) * | 2002-09-24 | 2004-04-15 | Combinatorx, Incorporated | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| WO2004028545A1 (en) * | 2002-09-25 | 2004-04-08 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| WO2004067006A1 (en) * | 2003-01-27 | 2004-08-12 | Pharmacia Corporation | Combination of a pde iv inhibitor and a tnf-alpha antagonist |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| WO2005110450A1 (en) * | 2004-05-17 | 2005-11-24 | Keio University | Medicinal composition and therapeutic method |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP1808446B1 (en) | 2004-07-16 | 2012-01-18 | Atsuo Sekiyama | Il-18 receptor antagonist and pharmaceutical composition containing the antagonist |
| US20070287689A1 (en) * | 2004-10-13 | 2007-12-13 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases |
| PL1921919T3 (en) | 2005-07-14 | 2012-09-28 | Lithera Inc | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
| ES2398480T3 (en) * | 2006-10-17 | 2013-03-19 | Lithera, Inc. | Procedures, compositions, and formulations for the treatment of thyroid eye disease |
| US7776331B1 (en) | 2007-01-16 | 2010-08-17 | Abbott Laboratories | Methods of treating plaque psoriasis |
| NZ580379A (en) | 2007-03-29 | 2012-10-26 | Abbott Lab | Crystalline anti-human il-12 antibodies |
| MX2010010265A (en) | 2008-03-18 | 2010-09-30 | Abbott Lab | Methods for treating psoriasis. |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| AU2011336869B2 (en) | 2010-11-24 | 2016-09-15 | Neothetics, Inc. | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
| WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
| CA3206106A1 (en) | 2021-02-10 | 2022-08-18 | Bhaskar Chaudhuri | Methods for ophthalmic delivery of roflumilast |
| AU2022353032A1 (en) * | 2021-09-22 | 2024-03-28 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| WO2024215900A2 (en) * | 2023-04-12 | 2024-10-17 | The Board Of Trustees Of The University Of Illinois | Agonists of small heterodimer partner for cancer therapy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3320125A (en) * | 1964-04-28 | 1967-05-16 | Merck & Co Inc | Inhalation aerosol composition |
| ATE92762T1 (en) * | 1989-09-08 | 1993-08-15 | Glaxo Group Ltd | MEDICATION. |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant |
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| MX9304585A (en) * | 1992-07-31 | 1994-03-31 | Glaxo Group Ltd | PHARMACEUTICAL FORMULATION IN AEROSOL, CAN SUITABLE TO RELEASE THE FORMULATION AND INHALER OF DOSE DOSE THAT COMPRISES THE CAN. |
| GB9426252D0 (en) * | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
| CA2218179A1 (en) * | 1995-04-14 | 1996-10-17 | Glaxo Wellcome Inc. | Metered dose inhaler for beclomethasone dipropionate |
-
1998
- 1998-03-12 WO PCT/US1998/004916 patent/WO1998041232A2/en not_active Ceased
- 1998-03-12 SK SK1221-99A patent/SK122199A3/en unknown
- 1998-03-12 PL PL98336464A patent/PL336464A1/en unknown
- 1998-03-12 IL IL13181598A patent/IL131815A0/en unknown
- 1998-03-12 SI SI9820032A patent/SI20110A/en unknown
- 1998-03-12 HU HU0104439A patent/HUP0104439A3/en unknown
- 1998-03-12 ES ES98912929T patent/ES2146192T1/en active Pending
- 1998-03-12 EP EP98912929A patent/EP0998300A1/en not_active Withdrawn
- 1998-03-12 AU AU67604/98A patent/AU734756B2/en not_active Ceased
- 1998-03-12 TR TR1999/02615T patent/TR199902615T2/en unknown
- 1998-03-12 KR KR1019997008524A patent/KR20000076420A/en not_active Withdrawn
- 1998-03-12 JP JP54063398A patent/JP2002504091A/en active Pending
- 1998-03-12 NZ NZ337769A patent/NZ337769A/en unknown
- 1998-03-12 BR BR9810409-8A patent/BR9810409A/en not_active IP Right Cessation
- 1998-03-12 CN CN98805124A patent/CN1269722A/en active Pending
- 1998-03-12 DE DE0998300T patent/DE998300T1/en active Pending
- 1998-03-12 CA CA002282845A patent/CA2282845A1/en not_active Abandoned
- 1998-03-12 ID IDW991185A patent/ID22975A/en unknown
-
1999
- 1999-09-17 NO NO994506A patent/NO994506L/en unknown
- 1999-10-13 BG BG103808A patent/BG103808A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000076420A (en) | 2000-12-26 |
| DE998300T1 (en) | 2001-03-01 |
| AU6760498A (en) | 1998-10-12 |
| JP2002504091A (en) | 2002-02-05 |
| BR9810409A (en) | 2000-08-22 |
| HUP0104439A3 (en) | 2002-08-28 |
| NZ337769A (en) | 2002-09-27 |
| WO1998041232A3 (en) | 2000-10-05 |
| BG103808A (en) | 2000-07-31 |
| WO1998041232A2 (en) | 1998-09-24 |
| ES2146192T1 (en) | 2000-08-01 |
| PL336464A1 (en) | 2000-06-19 |
| CN1269722A (en) | 2000-10-11 |
| IL131815A0 (en) | 2001-03-19 |
| CA2282845A1 (en) | 1998-09-24 |
| SI20110A (en) | 2000-06-30 |
| HUP0104439A2 (en) | 2002-04-29 |
| SK122199A3 (en) | 2000-12-11 |
| ID22975A (en) | 1999-12-23 |
| TR199902615T2 (en) | 2000-03-21 |
| EP0998300A1 (en) | 2000-05-10 |
| AU734756B2 (en) | 2001-06-21 |
| NO994506L (en) | 1999-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO994506D0 (en) | Methods and compositions for modulating susceptibility to corticosteroids | |
| NO20003096D0 (en) | Compositions and Methods for Treating ADD | |
| ATE297185T1 (en) | METHODS AND COMPOSITIONS FOR BLEACHING TEETH | |
| DE69838374D1 (en) | Processor and method for reducing its power consumption | |
| ID17437A (en) | METHODS AND COMPOSITIONS TO MAKE LIGHT SKIN | |
| IS5044A (en) | Method and new compounds to use with it | |
| NO991676D0 (en) | Methods and Compositions for Immunomodulation | |
| DE19781608T1 (en) | Methods and devices for dispensing compositions | |
| ATE351910T1 (en) | COMPOSITIONS AND METHODS CONTAINING OB-FUSION PROTEIN | |
| NO985354D0 (en) | Hair color compositions and methods | |
| KR960012626A (en) | Clips and how to make them | |
| ID20400A (en) | COMPOSITION AND METHODS FOR INHIBITING AGING DUE TO LIGHT ON SKIN | |
| DE69712736D1 (en) | CHOLESTERIC FLAKE | |
| DE69406920D1 (en) | ANALYT REACTIVE KTP COMPOSITION AND METHOD | |
| FI971349A7 (en) | Asphalt remover and method of use | |
| NO20006604D0 (en) | Methods and transdermal compositions for pain relief | |
| DK0977812T3 (en) | Asphalt compositions and processes for their preparation | |
| ID23809A (en) | ALGINATE COMPOSITIONS THAT CAN BE SUPPORTED | |
| NO985385L (en) | Bitumen compositions and processes for their preparation | |
| DK1051170T3 (en) | Use of Substituted Aminomethyl Chromas for Prevention of Nerve Degeneration and to Accelerate Nerve Regeneration | |
| ID22098A (en) | METHOD TO REMOVE CORETANS | |
| BR9708736A (en) | Bar composition | |
| NO991749D0 (en) | Compositions for use in concrete and concrete products made therefrom | |
| EP1073333A4 (en) | S-RABEPRAZOL COMPOSITIONS AND METHODS | |
| DE69908679D1 (en) | Procedure to continue |